These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 18258341)
1. [Designing an effective AIDS vaccine: strategies and current status]. Coutsinos Z; Absi Z; Henin Y; Guillet JG; Launay O Rev Med Interne; 2008 Aug; 29(8):632-41. PubMed ID: 18258341 [TBL] [Abstract][Full Text] [Related]
2. A review of vaccine research and development: the human immunodeficiency virus (HIV). Girard MP; Osmanov SK; Kieny MP Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298 [TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Girard MP; Osmanov S; Assossou OM; Kieny MP Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747 [TBL] [Abstract][Full Text] [Related]
4. Current issues in the development of a vaccine to prevent human immunodeficiency virus: insights from the society of infectious diseases pharmacists. Sahloff EG Pharmacotherapy; 2005 May; 25(5):741-7. PubMed ID: 15899735 [TBL] [Abstract][Full Text] [Related]
5. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Paris RM; Kim JH; Robb ML; Michael NL Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348 [TBL] [Abstract][Full Text] [Related]
6. Challenges in the development of an effective HIV vaccine: current approaches and future directions. Klein E; Ho RJ Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285 [TBL] [Abstract][Full Text] [Related]
7. Vaccine approaches currently in development. Gold D Body Posit; 1998 Jul; 11(7):34-5. PubMed ID: 11365616 [TBL] [Abstract][Full Text] [Related]
8. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. Dimitrov D; Kublin JG; Ramsey S; Corey L EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286 [TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions. Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788 [TBL] [Abstract][Full Text] [Related]
10. HIV vaccine research: the challenge and the way forward. Wang HB; Mo QH; Yang Z J Immunol Res; 2015; 2015():503978. PubMed ID: 25861656 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of primate models for AIDS. Haigwood NL AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617 [TBL] [Abstract][Full Text] [Related]
18. Prospects for a Globally Effective HIV-1 Vaccine. Excler JL; Robb ML; Kim JH Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model. Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672 [TBL] [Abstract][Full Text] [Related]
20. No vaccine against HIV yet--are we not perfectly equipped? Singh M Virol J; 2006 Aug; 3():60. PubMed ID: 16939652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]